Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib With Pemetrexed for Relapsed/Refractory CNS Lymphomas
NCT05681195Phase 2Recruiting
- Sponsor
- Baptist Health South Florida
- Start
- Apr 2024
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL), sponsored by Baptist Health South Florida. Primary endpoint: Best Overall Response Rate to Induction Therapy at 6 months. Started Apr 2024; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT05681195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681195.